U.S., Jan. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07367815) titled 'Allogeneic Adipose Tissue Derived-stem Cells in Alzheimer Disease' on Jan. 09.
Brief Summary: A3D is a phase I/II clinical trial. The primary objective is to evaluate the safety of allogeneic adipose tissue derived-stem cells (AdMSC) administered by intravenous (IV) route in mild to moderate Alzheimer disease (AD) using a dose escalation protocol.
Study Start Date: March 01
Study Type: INTERVENTIONAL
Condition:
Alzheimer Disease
Intervention:
DRUG: CellREADY(R) drug product IV dose of 50 millions
Allogeneic AdMSC (CellREADY(R) drug product), intravenous administration, dose of 50 millions.
Initially, 3 patients will receive ...